AbbVie (ABBV) Net Cash Flow (2012 - 2026)
AbbVie (ABBV) reported Net Cash Flow of $4.2 billion for Q1 2026, up 1265.92% year-over-year from $305.6 million in Q1 2025, and up 1115.57% on a QoQ basis from -$411.0 million in Q4 2025.
AbbVie (ABBV) has 15 years of Net Cash Flow data on file, last reported at $4.2 billion in Q1 2026.
- Quarterly Net Cash Flow rose 1265.92% year-over-year to $4.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 billion (up 132.64% YoY) and the FY2025 annual result came in at -$337.0 million, up 95.34% from the prior year.
- Net Cash Flow improved to $4.2 billion in Q1 2026 per ABBV's latest filing, from -$411.0 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $5.3 billion in Q1 2024 and bottomed at -$5.9 billion in Q3 2024.
- The 5-year median for Net Cash Flow is -$411.0 million (2025), against an average of -$15.5 million.
- The widest annual swing landed in 2022, when Net Cash Flow sank 368.55%; it then soared 1265.92% in 2026.
- Tracing ABBV's Net Cash Flow over 5 years: stood at -$2.7 billion in 2022, then surged by 81.31% to -$496.0 million in 2023, then tumbled by 240.12% to -$1.7 billion in 2024, then surged by 75.64% to -$411.0 million in 2025, then soared by 1115.57% to $4.2 billion in 2026.
- Per Business Quant, the three latest ABBV Net Cash Flow figures stand at $4.2 billion (Q1 2026), -$411.0 million (Q4 2025), and -$830.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | -2.05 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 2.00 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 4.17 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -9.27 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 75.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 544.00 Mn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -587.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.17 Bn |
| Mar 31, 2026 | 4.17 Bn |
| Dec 31, 2025 | -411.00 Mn |
| Dec 31, 2025 | -411.00 Mn |
| Sep 30, 2025 | -830.00 Mn |
| Sep 30, 2025 | -830.00 Mn |
| Jun 30, 2025 | 1.26 Bn |
| Jun 30, 2025 | 1.26 Bn |
| Mar 31, 2025 | -358.00 Mn |
| Mar 31, 2025 | -358.00 Mn |
| Dec 31, 2024 | -1.69 Bn |
| Dec 31, 2024 | -1.69 Bn |
| Sep 30, 2024 | -5.88 Bn |
| Sep 30, 2024 | -5.88 Bn |
| Jun 30, 2024 | -4.93 Bn |
| Jun 30, 2024 | -4.93 Bn |
| Mar 31, 2024 | 5.27 Bn |
| Mar 31, 2024 | 5.27 Bn |
| Dec 31, 2023 | -496.00 Mn |
| Dec 31, 2023 | -496.00 Mn |
| Sep 30, 2023 | 4.54 Bn |
| Sep 30, 2023 | 4.54 Bn |
| Jun 30, 2023 | 2.06 Bn |
| Jun 30, 2023 | 2.06 Bn |
| Mar 31, 2023 | -2.50 Bn |
| Mar 31, 2023 | -2.50 Bn |
| Dec 31, 2022 | -2.65 Bn |
| Dec 31, 2022 | -2.65 Bn |
| Sep 30, 2022 | 3.37 Bn |
| Sep 30, 2022 | 3.37 Bn |
| Jun 30, 2022 | 2.46 Bn |
| Jun 30, 2022 | 2.46 Bn |
| Mar 31, 2022 | -3.66 Bn |
| Mar 31, 2022 | -3.66 Bn |
| Dec 31, 2021 | -2.41 Bn |
| Dec 31, 2021 | -2.41 Bn |
| Sep 30, 2021 | 3.68 Bn |
| Sep 30, 2021 | 3.68 Bn |
| Jun 30, 2021 | -1.24 Bn |
| Jun 30, 2021 | -1.24 Bn |
| Mar 31, 2021 | 1.36 Bn |
| Mar 31, 2021 | 1.36 Bn |
| Dec 31, 2020 | 532.00 Mn |
| Dec 31, 2020 | 532.00 Mn |
| Sep 30, 2020 | 1.87 Bn |
| Sep 30, 2020 | 1.87 Bn |
| Jun 30, 2020 | -35.13 Bn |
| Jun 30, 2020 | -35.13 Bn |
| Mar 31, 2020 | 1.26 Bn |
| Mar 31, 2020 | 1.26 Bn |
| Dec 31, 2019 | 29.26 Bn |
| Dec 31, 2019 | 29.26 Bn |
| Sep 30, 2019 | 5.49 Bn |
| Sep 30, 2019 | 5.49 Bn |
| Jun 30, 2019 | 267.00 Mn |
| Jun 30, 2019 | 267.00 Mn |
| Mar 31, 2019 | -2.39 Bn |
| Mar 31, 2019 | -2.39 Bn |
| Dec 31, 2018 | -716.00 Mn |
| Dec 31, 2018 | -716.00 Mn |
| Sep 30, 2018 | 4.48 Bn |
| Sep 30, 2018 | 4.48 Bn |
| Jun 30, 2018 | -5.43 Bn |
| Jun 30, 2018 | -5.43 Bn |
| Mar 31, 2018 | -311.00 Mn |
| Mar 31, 2018 | -311.00 Mn |
| Dec 31, 2017 | 857.00 Mn |
| Dec 31, 2017 | 857.00 Mn |
| Sep 30, 2017 | -109.00 Mn |
| Sep 30, 2017 | -109.00 Mn |
| Jun 30, 2017 | 318.00 Mn |
| Jun 30, 2017 | 318.00 Mn |
| Mar 31, 2017 | -376.00 Mn |
| Mar 31, 2017 | -376.00 Mn |
| Dec 31, 2016 | -1.08 Bn |
| Dec 31, 2016 | -1.08 Bn |
| Sep 30, 2016 | -116.00 Mn |
| Sep 30, 2016 | -116.00 Mn |
| Jun 30, 2016 | -1.22 Bn |
| Jun 30, 2016 | -1.22 Bn |
| Mar 31, 2016 | -549.00 Mn |
| Mar 31, 2016 | -549.00 Mn |
| Dec 31, 2015 | -765.00 Mn |
| Dec 31, 2015 | -765.00 Mn |
| Sep 30, 2015 | 1.84 Bn |
| Sep 30, 2015 | 1.84 Bn |
| Jun 30, 2015 | -510.00 Mn |
| Jun 30, 2015 | -510.00 Mn |
| Mar 31, 2015 | -218.00 Mn |
| Mar 31, 2015 | -218.00 Mn |
| Dec 31, 2014 | 1.05 Bn |
| Dec 31, 2014 | 1.05 Bn |
| Sep 30, 2014 | -1.22 Bn |
| Sep 30, 2014 | -1.22 Bn |
| Jun 30, 2014 | 943.00 Mn |
| Jun 30, 2014 | 943.00 Mn |
| Mar 31, 2014 | -1.45 Bn |
| Mar 31, 2014 | -1.45 Bn |
| Dec 31, 2013 | 621.00 Mn |
| Dec 31, 2013 | 621.00 Mn |
| Sep 30, 2013 | 221.00 Mn |
| Sep 30, 2013 | 221.00 Mn |
| Jun 30, 2013 | 1.77 Bn |
| Jun 30, 2013 | 1.77 Bn |
| Mar 31, 2013 | 1.09 Bn |
| Mar 31, 2013 | 1.09 Bn |
| Dec 31, 2012 | 3.12 Bn |
| Dec 31, 2012 | 3.12 Bn |
| Sep 30, 2012 | 2.69 Bn |
| Sep 30, 2012 | 2.69 Bn |
| Jun 30, 2012 | 33.00 Mn |
| Jun 30, 2012 | 33.00 Mn |
| Mar 31, 2012 | 14.00 Mn |
| Mar 31, 2012 | 14.00 Mn |